Mabtech

Executive Summary

Mabtech is a privately held Swedish biotechnology company that has been a trusted provider of high-quality antibodies and immunoassay kits since 1986. With a strong focus on immunology and immunotherapy research, the company offers a range of cell-based analytical tools including ELISpot, FluoroSpot, ELISA, and its proprietary EYRAplex multiplex platform. Mabtech's products are designed to support research from discovery through clinical applications, emphasizing reliability and reproducibility. The company maintains a solid reputation in the academic and pharmaceutical research communities, though it operates in a competitive landscape with larger players. Given its long-standing presence and niche specialization, Mabtech is well-positioned to benefit from growing demand for immuno-oncology and vaccine research tools. However, as a private firm with limited public financials, growth projections are uncertain. The company's strategic focus on expanding its EYRAplex platform and entering clinical diagnostics could drive future value.

Upcoming Catalysts (preview)

• Q3 2026Launch of new EYRAplex multiplex assays for clinical research70% success
• TBDPartnership with a major pharma company for immunotherapy biomarker discovery50% success
• TBDExpansion into point-of-care diagnostics with novel antibody-based tests30% success